The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Summary The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Saved in:
Bibliographic Details
Published in:Journal of dermatological science 2008-06, Vol.50 (3), p.232-235
Main Authors: Sredni-Kenigsbuch, Dvora, Shohat, Michael, Shohat, Batia, Ben-Amitai, Dan, Chan, Chi-Chao, David, Michael
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - pharmacology
Child
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - immunology
Dermatology
Ethylenes - pharmacology
Humans
In Vitro Techniques
Interleukin-10 - metabolism
p38 Mitogen-Activated Protein Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.
ISSN:0923-1811
1873-569X
DOI:10.1016/j.jdermsci.2007.12.007